Aaron Etra, MD
Medical Oncology · New York, NYNPI 1730455809
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by National Marrow Donor Program at 39.2% of the total. Reporting peaked in 2023 at $8,296 and has fallen 90.4% since, to $798 in 2025.
Across 44 payments — averaging $432.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- National Marrow Donor Program$7K
- CSL Behring$7K
- Incyte Corporation$2K
- Kadmon Pharmaceuticals LLC$1K
- Genentech USA, Inc.$261
- Merck$191
- plus $506 from 6 others
Across 22 payments — averaging $5676.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$76K
- National Marrow Donor Program$49K
What the payments were for
- Consulting fees$10,97858%
- Speaking & faculty fees$7,23438%
- Food & beverage$7814%
- Entertainment$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| National Marrow Donor Program | 10 | $7,452 |
| CSL Behring | 8 | $6,740 |
| Incyte Corporation | 1 | $2,398 |
| Kadmon Pharmaceuticals LLC | 1 | $1,473 |
| Genentech USA, Inc. | 2 | $261 |
| Merck | 8 | $191 |
| Gilead | 7 | $188 |
| AstraZeneca | 1 | $150 |
| Sanofi-aventis U.S. LLC | 2 | $62 |
| Daiichi Sankyo Inc. | 2 | $55 |
| Eurofins Viracor, LLC | 1 | $26 |
| Pfizer | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$150
How this compares
$19,020 in reported general payments places this provider in the 65th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 64 | $1,028,451 |
| RezurockBelumosudil Mesylate | 33 | $565,495 |
| PromactaEltrombopag Olamine | 13 | $223,165 |
| NinlaroIxazomib Citrate | 11 | $145,755 |
| PrevymisLetermovir | 20 | $141,205 |
| CresembaIsavuconazonium Sulfate | 14 | $75,003 |
| Posaconazole | 32 | $24,818 |
| Atovaquone | 43 | $12,762 |
| BaracludeEntecavir | 14 | $12,587 |
| EliquisApixaban | 15 | $8,371 |
| Ursodiol | 18 | $2,635 |
| Acyclovir | 77 | $1,874 |
| ValacyclovirValacyclovir Hcl | 26 | $1,743 |
| Sirolimus | 11 | $1,117 |
| Triamcinolone Acetonide | 25 | $863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $2,398 | $1,028,45164 claims |
| Sanofi-aventis U.S. LLCRezurock | $62 | $565,49533 claims |
| MerckPrevymis | $191 | $141,20520 claims |
| PfizerEliquis | $26 | $8,37115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 498 medical oncology providers in New York.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.